If you have been diagnosed with glioblastoma, you have probably read that immunotherapy has improved outcomes in melanoma, lung cancer, and other solid tumors. The natural question is: why not brain tumors? The honest answer is that researchers are still working it out, and the picture has shifted significantly over the last five years. No immunotherapy is currently FDA-approved specifically for glioblastoma, but a growing number of trials are open. Which ones you can enter depends heavily on your tumor's molecular profile - the specific biological fingerprint left by your biopsy or surgical specimen.
Is any immunotherapy approved for glioblastoma right now?
No immunotherapy has received FDA approval specifically for glioblastoma as of 2025. Standard first-line treatment remains surgery, radiation, and temozolomide chemotherapy. Several immunotherapy approaches - including checkpoint inhibitors, cancer vaccines, and CAR-T cell therapy - are being studied in clinical trials, with eligibility often tied to specific molecular markers found in your tumor tissue.
Why the Brain Is a Hard Environment for Immunotherapy
The immune system has a complicated relationship with the brain. The blood-brain barrier - the tight cellular layer separating brain tissue from the bloodstream - limits which immune cells can enter and how freely they can circulate. Glioblastoma compounds this by actively suppressing immune responses in the tissue around it.
Researchers call this the "immunosuppressive tumor microenvironment." The tumor releases chemical signals that tell nearby immune cells to stand down. It also changes which surface proteins it displays over time, making it harder for the immune system to recognize and attack it consistently. These factors explain why checkpoint inhibitors that changed the prognosis in several other cancer types have so far failed to show a clear survival benefit in glioblastoma.
As the National Cancer Institute documented in a detailed analysis, the immunosuppressive environment within glioblastoma tumors remains one of the primary obstacles to effective immunotherapy in this disease.
Checkpoint Inhibitors: What the Large Trials Found
Checkpoint inhibitors work by blocking proteins that normally restrain immune cell activity. The most studied in glioblastoma are PD-1 inhibitors - nivolumab and pembrolizumab. Three large phase III trials specifically tested nivolumab:
- CheckMate 143 compared nivolumab with bevacizumab in recurrent glioblastoma. Nivolumab did not improve overall survival.
- CheckMate 498 tested nivolumab plus radiation in newly diagnosed patients with unmethylated MGMT promoter. Again, no survival benefit over chemotherapy plus radiation alone.
- CheckMate 548 added nivolumab to the standard Stupp protocol (radiation plus temozolomide) in patients with methylated MGMT. The combination did not outperform standard treatment.
These results were discouraging, but they generated important biological data. A genomic study published in Nature Medicine tracked 66 glioblastoma patients - including 17 who responded long-term to PD-1 inhibitors. It found that patients whose tumors carried MAPK signaling pathway alterations (such as PTPN11 or BRAF mutations) were more likely to respond to anti-PD-1 therapy, while PTEN mutations were enriched among non-responders. This kind of molecular stratification is now shaping how next-generation checkpoint inhibitor trials are designed.
If your tumor has undergone comprehensive genomic profiling, these markers may tell you whether a checkpoint inhibitor trial is worth pursuing. If your pathology report feels difficult to interpret, the guide to reading your glioblastoma pathology report explains what each molecular finding means in plain language.
Cancer Vaccines: Training the Immune System to Target the Tumor
Cancer vaccines for glioblastoma are not prevention vaccines. They are treatment vaccines, designed after diagnosis to train your immune system to attack tumor cells. Researchers are developing several approaches.
Personalized neoantigen vaccines analyze the specific mutations in your tumor and design a custom vaccine targeting proteins that exist only on your cancer cells. Because mutations differ from patient to patient, each vaccine is built from a sample of your own tumor tissue. Early-phase results have confirmed that these vaccines can generate measurable immune responses, though whether this translates into longer survival is still being tested.
Dendritic cell vaccines take immune cells called dendritic cells from your blood, expose them to tumor antigens in a lab, and reinfuse them to prime your immune system. The most studied version, DCVax-L, had phase III results published in JAMA Oncology in late 2022. The data showed that 13% of newly diagnosed patients treated with DCVax-L were alive at 60 months from randomization, compared with 5.7% in the standard-of-care control group. The trial's methodology has drawn scrutiny, and DCVax-L has not yet received FDA approval - but the long-term survival signal has kept it in active discussion.
EGFRvIII peptide vaccines target a specific rearranged form of the EGFR protein that appears on roughly 25-30% of glioblastomas but not on healthy brain tissue. The most studied version, rindopepimut, showed early promise in phase I and II trials but did not improve survival in the phase III ACT IV trial. Research has continued into next-generation EGFRvIII-targeting approaches, often combined with checkpoint blockade.
The National Brain Tumor Society maintains an updated listing of new brain tumor trials, including several vaccine-based studies currently recruiting. For a deeper look at how tumor vaccines work and which molecular markers determine eligibility, the article on personalized tumor vaccines for recurrent glioblastoma covers the current landscape in detail.
CAR-T Cell Therapy: Engineering Immune Cells to Find the Tumor
CAR-T (chimeric antigen receptor T-cell) therapy involves removing T-cells from your blood, reprogramming them in a lab to recognize specific proteins on glioblastoma cells, and infusing them back. In glioblastoma trials, these cells are often delivered directly into the brain cavity or spinal fluid rather than through a vein - an approach that may improve their ability to reach and persist within the tumor. Several molecular targets are being pursued:
- IL-13R-alpha-2 (IL-13Rα2): A protein overexpressed on many glioblastoma cells but rarely found in normal brain tissue. A phase I trial at City of Hope tested locoregional delivery in 65 patients with recurrent high-grade glioma and confirmed the approach was safe and feasible, establishing a recommended phase II dose.
- EGFRvIII: Present in approximately 25-30% of glioblastomas. Several trials are now combining EGFRvIII and IL-13Rα2 targeting in bivalent constructs - T-cells engineered to recognize both proteins simultaneously - to reduce the risk of the tumor escaping by losing one target.
- EGFR epitope 806: A newer approach targeting a broadly overexpressed form of EGFR through a specific binding site, being studied in EGFR-amplified, MGMT-unmethylated tumors.
Whether you qualify for any of these trials depends on which proteins your tumor expresses - information that comes only from immunohistochemical or molecular analysis of your biopsy tissue. If those tests were not performed at diagnosis, this is a concrete reason to revisit the pathology material.
Oncolytic Viruses: Turning an Infection Against the Tumor
Oncolytic viruses are modified viruses that selectively infect and destroy cancer cells. As tumor cells break apart, they release signals that may activate a broader immune response in surrounding tissue. Three approaches have advanced furthest in glioblastoma:
- PVSRIPO: A modified poliovirus delivered through a catheter directly into the tumor. Early data from Duke University showed a subset of patients with responses lasting more than a year after treatment.
- DNX-2401 (tasadenoturev): A modified adenovirus that has shown early signals of activity and is now being tested in combination with immune checkpoint inhibitors.
- G47Delta: A triple-mutated herpes simplex virus that received conditional approval in Japan in 2021 for recurrent glioblastoma - the first viral therapy approved anywhere for a brain tumor. It is not yet approved by the FDA or the European Medicines Agency, but its regulatory milestone in Japan has kept oncolytic virus research active in Western clinical programs.
How Your Molecular Profile Shapes Immunotherapy Eligibility
This is the section most directly useful when you are deciding what to ask for next. Immunotherapy eligibility in glioblastoma is not a single shared pool - most trials now stratify or restrict enrollment based on specific molecular findings from your tumor biopsy or surgical specimen.
MGMT promoter methylation is primarily associated with temozolomide response, but it also appears to influence the immune environment inside the tumor. Several trials enroll patients with methylated and unmethylated MGMT in separate cohorts because the immunological context differs between these groups. Knowing your MGMT status - and whether it was tested by pyrosequencing (more reliable) rather than immunohistochemistry alone - matters when you read trial eligibility language.
IDH mutation status is critical. IDH-mutant high-grade gliomas have different immune characteristics than IDH-wildtype glioblastoma. Most glioblastoma immunotherapy trials are designed for IDH-wildtype tumors, which account for the large majority of glioblastoma diagnoses. If your tumor is IDH-mutant, you may be excluded from trials labeled "glioblastoma" but may qualify for separate studies designed specifically for IDH-mutant grade 3 and 4 gliomas. These are two distinct populations in trial eligibility.
EGFRvIII expression is a key enrollment criterion for several vaccine and CAR-T trials. Immunohistochemistry detects it on your tumor tissue. If your initial pathology report does not mention EGFRvIII testing, it may not have been ordered - and this is worth asking about specifically, especially if you are at recurrence and evaluating trial options.
PD-L1 expression and tumor mutational burden (TMB) are standard checkpoint inhibitor biomarkers in other cancer types. PD-L1 appears in 60-70% of glioblastomas, but expression alone has not reliably predicted response to checkpoint inhibitors in glioblastoma the way it does in lung cancer or melanoma. TMB tends to be low in primary glioblastoma, which partially explains the limited response rate seen in large trials. However, recurrent glioblastoma treated with temozolomide can sometimes develop a hypermutated phenotype that raises TMB - which may matter for future checkpoint inhibitor eligibility in that setting.
PTEN and MAPK pathway alterations are not yet standard eligibility criteria, but early evidence suggests they predict who benefits from PD-1 blockade. A comprehensive next-generation sequencing (NGS) panel will detect these mutations. As trials become more precisely designed, these markers may become formal enrollment requirements rather than exploratory endpoints.
If you are unsure whether your tumor has been fully profiled for all relevant markers, this is one of the strongest practical reasons to seek an expert second review before settling on a next step. You may qualify for a trial your current team has not considered because a relevant marker was never tested. If that is where you are, you can request a personalised treatment review from the Art of Healing Cancer team to get an independent assessment of your molecular profile and what options it may open.
For a practical framework on finding and evaluating open trials, the article on clinical trial search strategy for glioblastoma walks through how to use ClinicalTrials.gov effectively and what questions to ask a trial coordinator before committing to enrollment.
Where the Field Is Heading
The field has largely moved past testing single immunotherapy agents in isolation. Current and upcoming trials are exploring combinations: checkpoint inhibitors paired with vaccines, CAR-T followed by checkpoint blockade, oncolytic viruses combined with anti-PD-1 therapy, and immunotherapy layered on top of Tumor Treating Fields. The logic is that no single approach is sufficient to overcome glioblastoma's immunosuppressive defenses - but stacking approaches may generate a self-sustaining immune response that individual agents cannot.
A 2025 review summarizing the global clinical trial landscape found that cancer vaccine studies represent the largest share of active glioblastoma immunotherapy trials (approximately 51%), followed by checkpoint inhibitors (26%), oncolytic viruses (12%), and CAR-T approaches (11%). Phase I trials still predominate - which reflects how early this field remains overall - but the number of phase II and III studies is growing as initial safety and signal data accumulate.
When to Talk to Your Doctor
Bring up immunotherapy trials with your neuro-oncologist if your tumor has recurred after standard treatment. Also ask if your molecular profile includes markers that appear in trial eligibility criteria, such as EGFRvIII expression, MAPK pathway alterations, elevated TMB, or BRAF mutations. Ask whether your team has performed comprehensive genomic profiling. If you are newly diagnosed, ask which trial options may run alongside or after first-line treatment.
Ask specifically whether your center is enrolling patients on any immunotherapy studies, and request a referral to a multidisciplinary brain tumor board if one is not already part of your care.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.